Overview

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
Pfizer
Treatments:
Desvenlafaxine Succinate